Biogen’s stock increased by 1% on Thursday following a positive opinion from Europe’s pharmaceutical regulator regarding their Alzheimer’s disease drug developed with Eisai. This decision reversed a previous ruling that had initially denied approval for the drug, indicating a positive shift in the regulatory landscape for the medication. The news of the favorable opinion boosted investor confidence and contributed to the rise in Biogen’s stock value.
Full Article
Starling Bank to scrap 3.25% interest rate from popular current account within days
Starling Bank is discontinuing its 3.25% interest rate on current accounts, making it no longer competitive in the savings market. Customers who were rejected for the new 4% easy-access savings account are considering complaints to the ombudsman, as only 41% were successful in opening an account. Despite the removal of interest, Starling's current account still offers useful features, such as no fees for spending abroad and helpful budgeting tools, though customers may want to explore...
Read more